A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis

  1. Cara C Boutte
  2. Christina E Baer
  3. Kadamba Papavinasasundaram
  4. Weiru Liu
  5. Michael R Chase
  6. Xavier Meniche
  7. Sarah M Fortune
  8. Christopher M Sassetti
  9. Thomas R Ioerger
  10. Eric J Rubin  Is a corresponding author
  1. Harvard T.H. Chan School of Public Health, United States
  2. University of Massachusetts Medical School, United States
  3. Texas A&M University, United States
  4. Harvard TH Chan School of Public Health, United States

Abstract

Regulation of cell wall assembly is essential for bacterial survival and contributes to pathogenesis and antibiotic tolerance in Mycobacterium tuberculosis (Mtb). However, little is known about how the cell wall is regulated in stress. We found that CwlM, a protein homologous to peptidoglycan amidases, coordinates peptidoglycan synthesis with nutrient availability. Surprisingly, CwlM is sequestered from peptidoglycan (PG) by localization in the cytoplasm, and its enzymatic function is not essential. Rather, CwlM is phosphorylated and associates with MurA, the first enzyme in PG precursor synthesis. Phosphorylated CwlM activates MurA ~30 fold. CwlM is dephosphorylated in starvation, resulting in lower MurA activity, decreased cell wall metabolism, and increased tolerance to multiple antibiotics. A phylogenetic analysis of cwlM implies that localization in the cytoplasm drove the evolution of this factor. We describe a system that controls cell wall metabolism in response to starvation, and show that this regulation contributes to antibiotic tolerance.

Article and author information

Author details

  1. Cara C Boutte

    Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Christina E Baer

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Kadamba Papavinasasundaram

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Weiru Liu

    Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Michael R Chase

    Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Xavier Meniche

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Sarah M Fortune

    Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Christopher M Sassetti

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Thomas R Ioerger

    Department of Computer Science, Texas A&M University, College Station, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Eric J Rubin

    Department of Immunology and Infectious Disease, Harvard TH Chan School of Public Health, Boston, United States
    For correspondence
    erubin@hsph.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, Boutte et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,463
    views
  • 980
    downloads
  • 86
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Cara C Boutte
  2. Christina E Baer
  3. Kadamba Papavinasasundaram
  4. Weiru Liu
  5. Michael R Chase
  6. Xavier Meniche
  7. Sarah M Fortune
  8. Christopher M Sassetti
  9. Thomas R Ioerger
  10. Eric J Rubin
(2016)
A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis
eLife 5:e14590.
https://doi.org/10.7554/eLife.14590

Share this article

https://doi.org/10.7554/eLife.14590

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Sasha L Evans, Bethany A Haynes ... Rivka L Isaacson
    Insight

    Nature has inspired the design of improved inhibitors for cancer-causing proteins.

    1. Biochemistry and Chemical Biology
    Gabriella O Estevam, Edmond Linossi ... James S Fraser
    Research Article

    Mutations in the kinase and juxtamembrane domains of the MET Receptor Tyrosine Kinase are responsible for oncogenesis in various cancers and can drive resistance to MET-directed treatments. Determining the most effective inhibitor for each mutational profile is a major challenge for MET-driven cancer treatment in precision medicine. Here, we used a deep mutational scan (DMS) of ~5764 MET kinase domain variants to profile the growth of each mutation against a panel of 11 inhibitors that are reported to target the MET kinase domain. We validate previously identified resistance mutations, pinpoint common resistance sites across type I, type II, and type I ½ inhibitors, unveil unique resistance and sensitizing mutations for each inhibitor, and verify non-cross-resistant sensitivities for type I and type II inhibitor pairs. We augment a protein language model with biophysical and chemical features to improve the predictive performance for inhibitor-treated datasets. Together, our study demonstrates a pooled experimental pipeline for identifying resistance mutations, provides a reference dictionary for mutations that are sensitized to specific therapies, and offers insights for future drug development.